Insight Into the Kinetic of Amyloid β (1–42) Peptide Self‐Aggregation: Elucidation of Inhibitors’ Mechanism of Action

ChemBioChem - Tập 8 Số 17 - Trang 2152-2161 - 2007
Manuela Bartolini1, Carlo Bertucci1, María Laura Bolognesi1, Andrea Cavalli1, Carlo Melchiorre1, Vincenza Andrisano1
1Department of Pharmaceutical Sciences, University of Bologna, Via Belmeloro 6, 40126 Bologna (Italy), Fax: (+39) 051‐2099734

Tóm tắt

AbstractThe initial transition of amyloid β (1–42) (Aβ42) soluble monomers/small oligomers from unordered/α‐helix to a β‐sheet‐rich conformation represents a suitable target to design new potent inhibitors and to obtain effective therapeutics for Alzheimer's disease. Under optimized conditions, this reliable and reproducible CD kinetic study showed a three‐step sigmoid profile that was characterized by a lag phase (prevailing unordered/α‐helix conformation), an exponential growth phase (increasing β‐sheet secondary structure) and a plateau phase (prevailing β‐sheet secondary structure). This kinetic analysis brought insight into the inhibitors' mechanism of action. In fact, an increase in the duration of the lag phase can be related to the formation of an inhibitor–Aβ complex, in which the non‐amyloidogenic conformation is stabilized. When the exponential rate is affected exclusively, such as in the case of Congo red and tetracycline, then the inhibitor affinity might be higher for the pleated β‐sheet structure. Finally, by adding the inhibitor at the end of the exponential phase, the soluble protofibrils can be disrupted and the Aβ amyloidogenic structure can revert into monomers/small oligomers. Congo red and tetracycline preferentially bind to amyloid in the β‐sheet conformation because both decreased the slope of the exponential growth, even if to a different extent, whereas no effect was observed for tacrine and galantamine. Some very preliminary indications can be derived about the structural requirements for binding to nonamyloidogenic or β‐sheet amyloid secondary structure for the development of potent antiaggregating agents. On these premises, memoquin, a multifunctional molecule that was designed to become a drug candidate for the treatment of Alzheimer's disease, was investigated under the reported circular dichroism assay and its anti‐amyloidogenic mechanism of action was elucidated.

Từ khóa


Tài liệu tham khảo

10.1097/01.jnen.0000240468.12543.af

10.1007/s00702-006-0575-6

10.1042/bst0300552

10.1126/science.1079469

10.1038/nn1372

10.1074/jbc.M500997200

10.1016/j.freeradbiomed.2006.01.021

10.1523/JNEUROSCI.1189-06.2006

10.1096/fj.01-0377com

10.1038/nature04533

10.1016/S0925-4439(00)00034-X

10.1002/jms.243

10.1096/fj.04-1764com

10.1021/bi060955f

10.1038/359322a0

10.1126/science.1439760

10.1074/jbc.272.35.22364

10.1074/jbc.274.36.25945

10.1006/jmbi.2001.4970

10.1074/jbc.M608207200

10.1002/pro.5560020312

10.3109/13506129509031881

10.1016/0003-2697(89)90046-8

Wood S. J., 1996, J. Biol. Chem., 271, 4086, 10.1074/jbc.271.8.4086

10.1006/abio.1998.2933

10.1073/pnas.93.3.1125

10.1021/bi982119e

10.1074/jbc.M410553200

10.1016/j.peptides.2006.04.022

10.1016/j.bbadis.2005.05.004

10.3109/13506129808995290

10.1016/S0065-3233(08)60320-4

10.1016/S0006-3495(93)81393-6

10.1006/jmbi.1994.1704

10.1016/S1074-5521(97)90255-6

10.1016/S1074-5521(97)90303-3

10.1073/pnas.96.7.3688

10.1006/jmbi.1998.2299

10.1021/bi061850f

10.1126/science.1853202

10.1016/0022-2836(92)90106-T

10.1111/j.1432-1033.1993.tb19893.x

10.1002/cbic.200500223

10.1074/jbc.M204168200

10.1146/annurev.biochem.66.1.385

10.1002/(SICI)1097-0282(199905)49:6<505::AID-BIP8>3.0.CO;2-I

Morgan C., 2004, Prog. Neurobiol., 74

V.Andrisano M.Bartolini M. L.Bolognesi C.Cavalli C.Melchiorre M.Recanatini (PCT Int. Appl. WO2003087035) pp. 74.

10.1016/S0006-2952(02)01514-9

10.1074/jbc.M210207200

Jao S. C., 1997, Int. J. Exp. Clin. Invest., 4, 240

10.3109/13506120009146831

10.1002/jnr.20025

10.1111/j.1471-4159.2005.03407.x

10.1016/j.bbapap.2005.06.005

10.1016/S0141-8130(97)00065-2

10.1016/S0021-9258(18)48529-8

10.1007/0-387-23226-5_18

10.2174/1389450043345290

10.1074/jbc.M005698200

10.2174/0929866053005845

10.1006/bbrc.2002.6745

10.1016/S0168-0102(97)00081-3

10.1042/0264-6021:3430419

Howlett D. R., 1999, Biochem. J., 340, 283, 10.1042/bj3400283

10.1021/bi002416v

10.1021/jm010045q

10.1016/S0197-4580(02)00121-5

10.1021/jf051985c

10.1021/bi060955f

10.1021/ja0600678

10.1002/ange.200700256

10.1002/anie.200700256

10.2174/1567205054367928

10.1523/JNEUROSCI.4391-04.2005

Thông tin
Thông tin xuất bản

ChemBioChem

Tập 8 Số 17

2152-2161

Thông tin tác giả